Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abcellera Biologics Inc (NQ: ABCL )

2.935 -0.035 (-1.18%)
Streaming Delayed Price Updated: 12:19 PM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 380,035
Open 3.000
Bid (Size) 2.930 (9)
Ask (Size) 2.940 (17)
Prev. Close 2.970
Today's Range 2.930 - 3.020
52wk Range 2.650 - 7.960
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry. 
Via The Motley Fool
AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD
To capitalize on the transition to more AI-focused drug development investors need to understand the drug development process and the financial health and market potential of those companies under... 
Via Talk Markets

Performance

YTD
-48.78%
-48.78%
1 Month
+1.21%
+1.21%
3 Month
-26.81%
-26.81%
6 Month
-46.73%
-46.73%
1 Year
-61.63%
-61.63%

More News

Read More
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
Via Talk Markets
3 Biotech Stocks That Can Gain Exponentially By Leveraging AI
Via Talk Markets
AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024
From AbCellera Biologics Inc.
Via Business Wire
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
Via Talk Markets
AI-Focused Drug Discovery Stocks Portfolio Down 4% W/e June 14th
Via Talk Markets
Down 57%, Is AbCellera Biologics a Buy on the Dip?
Via The Motley Fool
AI-Focused Drug Discovery Stocks Portfolio Down 2% In May; Up 4% Last Week
Via Talk Markets
AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
From AbCellera Biologics Inc.
Via Business Wire
Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week
Via Talk Markets
A $50B AI Drug Discovery Revolution Has Begun - Here Are 6 Stocks To Consider Investing In
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week
Via Talk Markets
3 Stock Gems Hiding in the Nasdaq
Via InvestorPlace
5 Of 7 AI Categories Rose, Slightly,Over Past Week
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
AbCellera Biologics (ABCL) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
ABCL Stock Earnings: AbCellera Biologics Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
AbCellera Reports Q1 2024 Business Results
From AbCellera Biologics Inc.
Via Business Wire
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
Via Talk Markets
AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies
From AbCellera Biologics Inc.
Via Business Wire
Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
Via Talk Markets
The 10 Stocks In The Clinical-Stage BioTech Drug Stocks Index Are Down 4% YTD
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
From AbCellera Biologics Inc.
Via Business Wire
The 7 Best Penny Stocks to Buy in Q2 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.